Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Royal Bank Of Canada's Rating of Aardvark Therapeutics on 10/23/2026

On October 23, 2026, Royal Bank Of Canada updated its outlook on Aardvark Therapeutics (NASDAQ:AARD) with the action "Set Price Target", setting a price target of $2.50. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Royal Bank Of Canada

DateCompanyAction
10/23/2026
Schindler Holding AG stock logo
SHLAF
Schindler
Reiterated Rating
10/23/2026
Essentra stock logo
FLRAF
Essentra
Reiterated Rating
10/23/2026
Bankinter, S.A. stock logo
BKIMF
Bankinter
Reiterated Rating
10/23/2026
Mullen Group Ltd. stock logo
MLLGF
Mullen Group
Reiterated Rating
10/23/2026
Brunswick Corporation stock logo
BC
Brunswick
Set Price Target
10/23/2026
GE Aerospace stock logo
GE
GE Aerospace
Set Price Target
More Ratings From Royal Bank Of Canada